A Phase 1 Study of Autologous Dendritic Cell Immunotherapy in Patients With mCRPC
転移性去勢抵抗性前立腺がん(mCRPC)患者における自家樹状細胞を用いたがん免疫療法の安全性を評価するための非盲検、単一施設、第 1 相試験
The goal of this clinical trial was to evaluate the safety of Cellgram-DC-PC, an autologous dendritic cell-based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).
調査の概要
詳細な説明
Cellgram-DC-PC is an autologous dendritic cell-based cancer immunotherapy developed for patients with metastatic castration-resistant prostate cancer (mCRPC). This was a Phase 1, single-center, open-label clinical trial designed to characterize the safety profile of Cellgram-DC-PC following administration in patients with mCRPC.
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
-
Seoul、韓国
- Asan medical center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
19 and under 80 years
-
Histologically confirmed prostate adenocarcinoma
-
Patients with stage M1a or M1b with extrapelvic lymph nodes and bone metastases
-
Patients diagnosed with castration-resistant prostate cancer after failure of male hormone deprivation therapy (Castrate levels of testosterone <50 ng/dL) and If either a or b is satisfied:
- Biochemical progression: Prostate Specific Antigen (PSA) increases three times in a row at 1 week intervals, two 50% increases compared to the lowest point, PSA> 2ng/mL, or
- Radiological progression: appearance of new lesions; 2 or more new lesions on the bone scan
-
Asymptomatic or mild patients after previous treatment
- Patients who have not used narcotic analgesics within 21 days prior to enrollment
- Patients with an average weekly pain of less than 4 on the Visual Analogue Scale(VAS) (out of 10)
-
Combination of Luteinizing hormone-releasing hormone(LHRH) analogs (leuprolide (Lupron, Viadur, Eligard) and goserelin (Zoladex, etc.) for the inhibition of gonadotropin is allowed
-
Whole body performance status: European Cooperative Oncology Group(ECOG) 0~1
-
Patients whose life expectancy is at least 6 months or longer
-
Hb ≥ 8.0g/dL, Absolute Neutrophil Count(ANC) ≥ 1,500/mm3, Platelets ≥ 100,000/mm3
-
Serum Creatinine ≤ 2.0 x Upper Limit of Normal(ULN) or Calculated Creatinine Clearance > 30mL/min
-
Total Bilirubin ≤ 1.5 x ULN or Direct bilirubin ≤ ULN, Aminotransferase (AST)/Alanine aminotransferase(ALT) <2.5 x ULN
-
Patients who did not receive surgery, radiation therapy, or immunotherapy within the last 6 weeks and recovered from side effects
-
Patients who agreed to use medically recognized contraceptive methods during the clinical trial participation period
-
Patients who voluntarily participated in clinical trials and signed the Informed Contents Form (ICF)
Exclusion Criteria:
- Patients who have a local recurrence and are scheduled for local treatment.
- Patients with malignant tumors other than non-melanoma skin cancer in the past 3 years
- Patients with visceral metastases (metastases to the lungs, liver, adrenal glands, peritoneum, brain, etc.)
- Patients who previously received anti-tumor immunotherapy (anti-PD1, anti-PDL1 or anti-PDL2, etc.) or participated in immunotherapy-related clinical trials
- Patients with active autoimmune diseases requiring systemic immunosuppression treatment (e.g., immunosuppressants such as cyclosporin A or azathioprine or steroids for disease control)
- Patients with medical conditions requiring continuous or intermittent administration of systemic steroids or immunosuppressants
- Patients who received blood products (limited to whole blood products) within 4 weeks of screening criteria, or patients who received colony stimulating factors (Colony Stimulating Factor or recombinant Erythropoietin)
- Patients with a history of organ or hematopoietic stem cell transplantation
- Patients with acute or chronic infections requiring systemic treatment
- Patients known to be infected with human immunodeficiency virus (HIV)/serum positive
- Patients with active hepatitis A, B or C
- Patients with untreated syphilis (Fluorescent Treponemal Antibody Absorption Test (FTA-ABS) Immunoglobulin M positive patients)
- Patients expected to require therapeutic biotherapy or immunotherapy
- Patients who received live virus vaccines (e.g. measles, mumps, rubella, chickenpox, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), oral typhoid vaccine, Flu-Mist, etc.) within 30 days
- Patients with a history of anaphylaxis to gentamicin
- Others, if the person in charge of the study determines that it is not suitable for the clinical trial
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Cellgram-DC-PC
Participants received Cellgram-DC-PC by subcutaneous injection near the inguinal lymph nodes. |
Patients received three subcutaneous injections of Cellgram-DC-PC (autologous dendritic cells) near the inguinal lymph nodes at Weeks 0, 2, and 4.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Adverse Event
時間枠:From informed consent to the end of treatment at Week 28.
|
Adverse events (AEs) were assessed for severity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. |
From informed consent to the end of treatment at Week 28.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Immune Response
時間枠:At baseline (Week 0), Week 4, Week 8, Week 16, and Week 28.
|
Tumor antigen-specific immune responses were evaluated by measuring changes in serum IFN-γ and IL-12 levels and antigen-specific T-cell responses following administration of the investigational product. |
At baseline (Week 0), Week 4, Week 8, Week 16, and Week 28.
|
|
Change in Prostate-Specific Antigen (PSA)
時間枠:At baseline (Week 0), Week 2, Week 4, Week 8, Week 16, and Week 28.
|
Exploratory efficacy was evaluated by measuring changes in prostate-specific antigen (PSA) levels from pre-treatment (Week 0) to post-treatment assessment. |
At baseline (Week 0), Week 2, Week 4, Week 8, Week 16, and Week 28.
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:BUMJIN LIM, Ph.D、Asan Medical Center
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- PMC-DC-01
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Individual participant data will not be made available to other researchers.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。